EP4684801A1 — Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
Assigned to Adocia SAS · Expires 2026-01-28 · 0y expired
What this patent protects
The invention relates to a composition comprising semaglutide, cagrilintide and a co-polyamino acid (PLG) bearing carboxylate charges and hydrophobic radicals, said composition being in the form of aqueous injectable solution at pH between 5.0 to 6.0.
USPTO Abstract
The invention relates to a composition comprising semaglutide, cagrilintide and a co-polyamino acid (PLG) bearing carboxylate charges and hydrophobic radicals, said composition being in the form of aqueous injectable solution at pH between 5.0 to 6.0.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.